hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06365918 id: 2023-0836 id: NCI-2024-03236 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2028-03-22 date: 2030-03-22 date: 2024-04-15 date: 2024-04-15 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To find the recommended dose of the investigational drug VG2025 that can be given intraperitoneally (given directly into the abdominal cavity) to participants with advanced solid tumors. conditions: Advanced Solid Tumor conditions: Carcinomatosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 21 type: ESTIMATED name: VG2025 measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Siqing Fu, MD,PHD role: CONTACT phone: 713-792-4318 email: siqingfu@mdanderson.org name: Siqing Fu, MD,PHD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06365905 id: 23-011680 id: NCI-2024-02550 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 23-011680 type: OTHER domain: Mayo Clinic in Rochester briefTitle: Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding overallStatus: RECRUITING date: 2024-06-01 date: 2027-06-30 date: 2027-06-30 date: 2024-04-15 date: 2024-04-16 name: Mayo Clinic class: OTHER briefSummary: This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions. conditions: Endometrial Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Non-Interventional Study measure: Accuracy of artificial intelligence (AI) algorithm applied to transvaginal ultrasound (TVUS) sex: FEMALE minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: NOT_YET_RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Kristina A. Butler, M.D., M.S. role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Florida status: NOT_YET_RECRUITING city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Christopher C. DeStephano, M.D., M.P.H. role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Gretchen E. Glaser, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06365892 id: 22-36548 briefTitle: Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-01-01 date: 2026-01-01 date: 2024-04-15 date: 2024-04-15 name: University of California, San Francisco class: OTHER briefSummary: This study aims to investigate the effects of conditioning with open-label placebos on standard postoperative treatment for patients undergoing surgery for idiopathic scoliosis in a randomized controlled, 6-week trial with 64 AIS patients randomly assigned to one of two arms: Open-label Placebo (COLP) + treatment as usual TAU / TAU control. The study involves collecting data from your child's medical record. At each regular clinic visit, the patient clinical data will be collected by the research coordinator. Surveys will be collected including:• PROMIS for the age group 10 to 18 years. conditions: Adolescent Idiopathic Scoliosis (AIS) studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Both arms - Open-label Placebo (COLP) and Treatment As Usual (TAU) primaryPurpose: TREATMENT masking: NONE maskingDescription: Blinding of patients and providers will not be feasible due to the nature of the study. count: 64 type: ESTIMATED name: open-label placebo name: Treatment as usual measure: The total amount of opioids consumed in oral morphine equivalents (OMEs) following surgery measure: Weekly level of mobility and change from baseline in mobility on the Patient-Reported Outcome Measurement Information System (PROMIS) Numeric Rating Scale Pediatric Mobility Short Form 7a at week 6. measure: Weekly level of anxiety and change from baseline in anxiety levels on the Patient-Reported Outcome Measurement Information System (PROMIS) Numeric Rating Scale Anxiety Short Form 8a at week 6. measure: Weekly level of depressive symptoms and change from baseline in depressive symptoms on the Patient-Reported Outcome Measurement Information System (PROMIS) Numeric Rating Scale Depressive Symptoms Short Form 8a at week 6. measure: The duration of time in days following surgery until patients establish Independence with Physical Therapy measure: The length of time in days following surgery until discharge from the hospital measure: The length of time in days following surgery until participant returns to school measure: Whether participants experience urinary retention following surgery. measure: Whether participants experience constipation measured by the number of days between surgery and first bowel movement measure: Whether participants experience an oxygen requirement and the duration of the requirement following surgery. sex: ALL minimumAge: 10 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University of California, San Francisco city: San Francisco state: California zip: 94158 country: United States lat: 37.77493 lon: -122.41942 hasResults: False
nctId: NCT06365879 id: CMAB007-003 briefTitle: To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-11-01 date: 2026-05-01 date: 2024-04-15 date: 2024-04-15 name: Taizhou Mabtech Pharmaceutical Co.,Ltd class: INDUSTRY briefSummary: This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria conditions: Chronic Spontaneous Urticaria studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 392 type: ESTIMATED name: CMAB007 name: Xolair measure: Change From Baseline of the Itch Severity Score (ISS7) Score At Week 12 measure: Change From Baseline of Urticaria Activity Score (UAS7) At Week 12 measure: Change From Baseline of Number of Hives Score (NHS7) At Week 12 measure: Time to ISS7 MID Response by Week 12 measure: Percentage of Patients With UAS7≤6 at Week 12 measure: Percentage of Patients With ISS7 Minimally Important Difference (MID) at Week 12 measure: Change From Baseline of Urticaria Control Test (UCT) at Week 12 measure: Percentage of Patients With UCT≥12 at Week 12 measure: Percentage of Complete Controls (UCT=16) at Week 12 measure: Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12 measure: Percentage of Complete Responders (UAS7=0) at Week 12 measure: Percentage of Angioedema-free Days From Week 4 to Week 12 measure: Incidence of adverse events measure: Immunogenicity measure: AUC0-t measure: AUC0-inf measure: Half time measure: Cmax measure: Tmax measure: Clearance Rate measure: Apparent Volume of Distribution measure: Level of Total IgE and Free IgE sex: ALL minimumAge: 15 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06365866 id: 2022-06-008B briefTitle: Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer. overallStatus: RECRUITING date: 2024-02-19 date: 2024-12 date: 2024-12 date: 2024-04-15 date: 2024-04-15 name: Taipei Veterans General Hospital, Taiwan class: OTHER_GOV briefSummary: The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer. conditions: Esophageal Neoplasms conditions: Head and Neck Neoplasms conditions: Gastrointestinal Neoplasms conditions: Digestive System Diseases conditions: Digestive System Neoplasms conditions: Esophageal Diseases conditions: Neoplasms by Site conditions: Gastrointestinal Diseases conditions: Neoplasms studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Add-on treatment to standard treatment (fixed doses allowing dose reduction or dose delay according to the tolerability of individual patients); No control group. primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: "BRAXX" Esophageal Brachytherapy Applicator. name: Add-on of intraluminal brachytherapy measure: To estimate the local control rate at primary tumor site. measure: To estimate overall response rate. measure: To estimate distant metastasis rate. measure: To estimate progression-free survival rate. measure: To estimate overall survival status. measure: To estimate toxicity analysis. measure: To estimate adverse event. sex: ALL minimumAge: 20 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Veterans General Hospital status: RECRUITING city: Taipei zip: 11217 country: Taiwan name: Pin-I Huang, Ph.D. role: CONTACT phone: +886 955-275-822 email: pihuang@vghtpe.gov.tw name: Pin-I Huang, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06365840 id: IMC-001-202 briefTitle: A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor acronym: TMB-H overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2027-12 date: 2024-04-15 date: 2024-04-15 name: ImmuneOncia Therapeutics Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients. conditions: TMB-H conditions: Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: IMC-001 measure: ORR sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06365827 id: AZ293/20 briefTitle: Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI) acronym: aMIKI overallStatus: ACTIVE_NOT_RECRUITING date: 2022-03-01 date: 2023-12-31 date: 2024-07-31 date: 2024-04-15 date: 2024-04-22 name: University of Giessen class: OTHER briefSummary: Acute mesenteric ischemia (AMI) is a severe condition that might occur after cardiovascular surgery. Several risk factors for AMI, such as multimorbidity, the use of vasopressors, and an increase in inflammatory markers have been identified in the past. However, these risk factors also seem to influence the blood and urine levels of I-FABP. This prospective pilot study intends to evaluate the value of perioperatively assessed I-FABP levels and to correlate these values with clinical or angiographic findings in mesenteric ischemia to improve a standardised diagnosis. conditions: Cardiac Surgery With Cardiopulmonary Bypass conditions: Acute Mesenteric Ischemia conditions: Acute Kidney Injury conditions: Non-Occlusive Mesenteric Ischaemia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 500 type: ACTUAL name: observational study measure: Concentration of I-FABP values with/and without acute mesenteric ischemia measure: Time interval to mesenteric ischemia measure: Overall mortality rate measure: Correlation of I-FABP with biomarkers of acute kidney injury measure: Association of mesenteric ischemia with hypercoagulable states measure: Incidence of stroke measure: Association of I-FABP level and multi-organ failure or cardiovascular mortality sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Giessen, Cardiovascular surgery city: Giessen state: Hessen zip: 35392 country: Germany lat: 50.58727 lon: 8.67554 hasResults: False
nctId: NCT06365814 id: ERASforNACT briefTitle: ERAS for Gastric Cancer Patients After NACT overallStatus: COMPLETED date: 2023-10-01 date: 2024-04-01 date: 2024-04-01 date: 2024-04-15 date: 2024-04-15 name: The Affiliated Hospital of Qingdao University class: OTHER briefSummary: Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress responses. However, whether this approach is safe and feasible for gastric cancer patients received minimally invasive radical gastrectomy after NACT remained determined. So, the objective of this study is to investigate the effects of ERAS for this special group of gastric cancer patients.
Materials and Methods: The data of gastric cancer patients who underwent minimally invasive radical gastrectomy after NACT were collected in this retrospective cohort study. Patients were divided into an ERAS group and a conventional group based on whether they received perioperative ERAS management. Propensity score matching was conducted to eliminate bias. Pre- and postoperative inflammatory and nutritional marker levels, postoperative complications, recovery indices and 3-year OS and RFS were observed. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 252 type: ACTUAL name: enhanced recovery after surgery name: conventional perioperative management measure: postoperative infectious complications measure: postoperative recovery parameter measure: blood test result measure: 3-year overall survival measure: 3-years recurrence-free survival sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital city: Qingdao state: Shandong zip: 266000 country: China lat: 36.06488 lon: 120.38042 hasResults: False
nctId: NCT06365801 id: 2022YFC3500401-IBS briefTitle: Investigation of Acupoint in Irritable Bowel Syndrome Based on Biological Characteristics overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2025-12 date: 2024-04-15 date: 2024-04-15 name: The Third Affiliated hospital of Zhejiang Chinese Medical University class: OTHER briefSummary: Irritable bowel syndrome (IBS) is a common functional disorder of the digestive system characterized by recurrent abdominal pain associated with bowel movements or changes in bowel habits. Although there are reviews and guidelines for treating IBS, the complexity and diversity of IBS manifestations make treatment difficult. By detecting and exploring the biological characteristics presented by the relevant meridian point reaction, this project clarified the specificity and regularity of the connection between the acupoint and the Zangfu reflected by this phenomenon, and conducted correlation analysis based on the intestinal flora, tryptophan metabolite levels and related scales of patients with IBS. conditions: Irritable Bowel Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Pain sensitivity measure: Thermal radiation characteristics measure: Microcirculation characteristics measure: Electrical characteristics measure: Biological ultra-weak luminescence measure: Intestinal flora measure: Tryptophan metabolites measure: Bristol Fecal Traits Grading Scale measure: Severity of IBS (IBS-SSS) measure: IBS Quality of Life (IBS-QOL ) measure: TCM Constitution Survey measure: Gastrointestinal Symptoms Rating Scale (GSRS) measure: Self-Rating Anxiety Scale (SAS) measure: Self-Rating Depression Scale (SDS) measure: Pittsburgh Sleep Quality Index (PSQI) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06365775 id: TJ-IRB20221229 briefTitle: Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss overallStatus: NOT_YET_RECRUITING date: 2024-04-23 date: 2026-11-23 date: 2026-11-23 date: 2024-04-15 date: 2024-04-15 name: Dan Bing class: OTHER briefSummary: The goal of this observational study is to describe the multi-omics characteristics and to learn about the prognostic factors in patients with idiopathic sudden sensorineural hearing loss (SSNHL). The main problems it aims to deal with are:
Participants will be received audiological tests, blood specimen collection and radiological examination. Researchers will explore the relationship between the multi-omics data and the prognosis and develop the predictive model. conditions: Sudden Sensorineural Hearing Loss conditions: Hearing Loss, Sensorineural conditions: Hearing Loss, Sudden studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED measure: Pure tone audiometry (PTA) measure: Speech reception thresholds measure: Speech discrimination scores measure: Variant detection efficiency measure: Exome coverage measure: Genome-wide variant distribution measure: Head MRI measure: Inner Ear MRI sex: ALL minimumAge: 4 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06365762 id: CK-0103 briefTitle: The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract overallStatus: COMPLETED date: 2006-01-01 date: 2006-12-31 date: 2007-04-30 date: 2024-04-15 date: 2024-04-16 name: Livionex Inc. class: INDUSTRY briefSummary: The study objectives were:
* To determine the optimal clinical dose of EDTA ophthalmic solution (C-KAD) which to proceed into pivotal study(s). conditions: Age Related Cataracts studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 111 type: ACTUAL name: EDTA Ophthalmic Solution 2.6% name: EDTA Ophthalmic Solution 1.3% name: Saline Solution (Placebo) measure: Contrast Sensitivity (Mesopic) Responder Analysis measure: Cumulative Improvement in Contrast Sensitivity (Mesopic) measure: Mean Change in Contrast Sensitivity (Mesopic) measure: Mean Change in Best-Corrected Visual Acuity (BCVA) measure: Pentacam Imaging sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St Mary's Eye Specialists, Inc. city: San Francisco state: California zip: 94117 country: United States lat: 37.77493 lon: -122.41942 facility: Hunkeler Eye Institute city: Overland Park state: Kansas zip: 66210 country: United States lat: 38.98223 lon: -94.67079 facility: The Johns Hopkins Hospital & Health System, Wilmer Eye Institute city: Lutherville state: Maryland zip: 21093 country: United States lat: 39.42122 lon: -76.62608 facility: Harvard Medical School, Massachusetts Eye and Ear Infirmary city: Boston state: Massachusetts zip: 02114 country: United States lat: 42.35843 lon: -71.05977 facility: Charlotte Eye, Ear, Nose, and Throat Associates city: Charlotte state: North Carolina zip: 28210 country: United States lat: 35.22709 lon: -80.84313 facility: University of Utah, John Moran Eye Center city: Salt Lake City state: Utah zip: 84132 country: United States lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06365749 id: TJ-IRB20221228 briefTitle: Genetic Feature of Congenital Hearing Loss in Chinese Population overallStatus: NOT_YET_RECRUITING date: 2024-04-23 date: 2026-11-23 date: 2026-11-23 date: 2024-04-15 date: 2024-04-15 name: Dan Bing class: OTHER briefSummary: Congenital hearing loss, as well as hearing loss present at birth, is one of the most common chronic conditions in children, with a prevalence of permanent bilateral hearing loss of 2.83 per 1000 children of primary school age, which is mainly caused by genetic factors. The goal of this observational study is to learn about novel causative genes in infants with hearing loss in the Chinese population. The main problem it aims to deal with are:
Participants will be asked to receive audiological tests and collection of the peripheral blood sample. conditions: Congenital Hearing Loss conditions: Congenital Deafness studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Whole exome sequencing data measure: TEOAE-based otoacoustic emissions test outcome measure measure: Auditory brainstem response testing measure: Acoustic impedance measure: Audiogram sex: ALL maximumAge: 6 Months stdAges: CHILD hasResults: False
nctId: NCT06365736 id: 240310 briefTitle: The Effect of a Contemplative Nature-based Intervention on Spiritual Well-being overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2024-09-04 date: 2024-09-04 date: 2024-04-15 date: 2024-04-15 name: University of Twente class: OTHER briefSummary: The goal of this randomized control trial is to test if contemplating in nature could benefit spiritual well-being in general adults. The main question it aims to answer is: